-
Microbiome and metabolome insights into the role of the gastrointestinal-brain axis in neurodegenerative diseases: unveiling potential therapeutic targets
Authors:
Helena U. Zacharias,
Christoph Kaleta,
Francois Cossais,
Eva Schaeffer,
Henry Berndt,
Lena Best,
Thomas Dost,
Svea Glüsing,
Mathieu Groussin,
Mathilde Poyet,
Sebastian Heinzel,
Corinna Bang,
Leonard Siebert,
Tobias Demetrowitsch,
Frank Leypoldt,
Rainer Adelung,
Thorsten Bartsch,
Anja Bosy-Westphal,
Karin Schwarz,
Daniela Berg
Abstract:
Due to the aging of the world population and westernization of lifestyles, the prevalence of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) is rapidly rising and is expected to put a strong socioeconomic burden on health systems worldwide. Due to the limited success of clinical trials of therapies against neurodegenerative diseases, research has extended i…
▽ More
Due to the aging of the world population and westernization of lifestyles, the prevalence of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) is rapidly rising and is expected to put a strong socioeconomic burden on health systems worldwide. Due to the limited success of clinical trials of therapies against neurodegenerative diseases, research has extended its scope to a systems medicine point of view, with a particular focus on the gastrointestinal-brain axis as a potential main actor in disease development and progression. Microbiome as well as metabolome studies along the gastrointestinal-brain axis have already revealed important insights into disease pathomechanisms. Both the microbiome and metabolome can be easily manipulated by dietary and lifestyle interventions, and might thus offer novel, readily available therapeutic options to prevent the onset as well as the progression of PD and AD. This review summarizes our current knowledge on the association between microbiota, metabolites, and neurodegeneration in light of the gastrointestinal-brain axis. In this context, we also illustrate state-of-the art methods of microbiome and metabolome research as well as metabolic modeling that facilitate the identification of disease pathomechanisms. We conclude our review with therapeutic options to modulate microbiome composition to prevent or delay neurodegeneration and illustrate potential future research directions to fight PD and AD.
△ Less
Submitted 19 August, 2022;
originally announced August 2022.
-
DRAGON: Determining Regulatory Associations using Graphical models on multi-Omic Networks
Authors:
Katherine H. Shutta,
Deborah Weighill,
Rebekka Burkholz,
Marouen Ben Guebila,
Dawn L. DeMeo,
Helena U. Zacharias,
John Quackenbush,
Michael Altenbuchinger
Abstract:
The increasing quantity of multi-omics data, such as methylomic and transcriptomic profiles, collected on the same specimen, or even on the same cell, provide a unique opportunity to explore the complex interactions that define cell phenotype and govern cellular responses to perturbations. We propose a network approach based on Gaussian Graphical Models (GGMs) that facilitates the joint analysis o…
▽ More
The increasing quantity of multi-omics data, such as methylomic and transcriptomic profiles, collected on the same specimen, or even on the same cell, provide a unique opportunity to explore the complex interactions that define cell phenotype and govern cellular responses to perturbations. We propose a network approach based on Gaussian Graphical Models (GGMs) that facilitates the joint analysis of paired omics data. This method, called DRAGON (Determining Regulatory Associations using Graphical models on multi-Omic Networks), calibrates its parameters to achieve an optimal trade-off between the network's complexity and estimation accuracy, while explicitly accounting for the characteristics of each of the assessed omics "layers." In simulation studies, we show that DRAGON adapts to edge density and feature size differences between omics layers, improving model inference and edge recovery compared to state-of-the-art methods. We further demonstrate in an analysis of joint transcriptome - methylome data from TCGA breast cancer specimens that DRAGON can identify key molecular mechanisms such as gene regulation via promoter methylation. In particular, we identify Transcription Factor AP-2 Beta (TFAP2B) as a potential multi-omic biomarker for basal-type breast cancer. DRAGON is available as open-source code in Python through the Network Zoo package (netZooPy v0.8; netzoo.github.io).
△ Less
Submitted 21 September, 2022; v1 submitted 4 April, 2021;
originally announced April 2021.
-
Fully integrative data analysis of NMR metabolic fingerprints with comprehensive patient data: a case report based on the German Chronic Kidney Disease (GCKD) study
Authors:
Helena U. Zacharias,
Michael Altenbuchinger,
Stefan Solbrig,
Andreas Schäfer,
Mustafa Buyukozkan,
Ulla T. Schultheiß,
Fruzsina Kotsis,
Anna Köttgen,
Jan Krumsiek,
Fabian J. Theis,
Rainer Spang,
Peter J. Oefner,
Wolfram Gronwald,
GCKD study investigators
Abstract:
Omics data facilitate the gain of novel insights into the pathophysiology of diseases and, consequently, their diagnosis, treatment, and prevention. To that end, it is necessary to integrate omics data with other data types such as clinical, phenotypic, and demographic parameters of categorical or continuous nature. Here, we exemplify this data integration issue for a study on chronic kidney disea…
▽ More
Omics data facilitate the gain of novel insights into the pathophysiology of diseases and, consequently, their diagnosis, treatment, and prevention. To that end, it is necessary to integrate omics data with other data types such as clinical, phenotypic, and demographic parameters of categorical or continuous nature. Here, we exemplify this data integration issue for a study on chronic kidney disease (CKD), where complex clinical and demographic parameters were assessed together with one-dimensional (1D) 1H NMR metabolic fingerprints. Routine analysis screens for associations of single metabolic features with clinical parameters, which requires confounding variables typically chosen by expert knowledge to be taken into account. This knowledge can be incomplete or unavailable. The results of this article are manifold. We introduce a framework for data integration that intrinsically adjusts for confounding variables. We give its mathematical and algorithmic foundation, provide a state-of-the-art implementation, and give several sanity checks. In particular, we show that the discovered associations remain significant after variable adjustment based on expert knowledge. In contrast, we illustrate that the discovery of associations in routine analysis can be biased by incorrect or incomplete expert knowledge in univariate screening approaches. Finally, we exemplify how our data integration approach reveals important associations between CKD comorbidities and metabolites. Moreover, we evaluate the predictive performance of the estimated models on independent validation data and contrast the results with a naive screening approach.
△ Less
Submitted 8 October, 2018;
originally announced October 2018.
-
Scale-invariant biomarker discovery in urine and plasma metabolite fingerprints
Authors:
Helena U. Zacharias,
Thorsten Rehberg,
Sebastian Mehrl,
Daniel Richtmann,
Tilo Wettig,
Peter J. Oefner,
Rainer Spang,
Wolfram Gronwald,
Michael Altenbuchinger
Abstract:
Motivation: Metabolomics data is typically scaled to a common reference like a constant volume of body fluid, a constant creatinine level, or a constant area under the spectrum. Such normalization of the data, however, may affect the selection of biomarkers and the biological interpretation of results in unforeseen ways.
Results: First, we study how the outcome of hypothesis tests for differenti…
▽ More
Motivation: Metabolomics data is typically scaled to a common reference like a constant volume of body fluid, a constant creatinine level, or a constant area under the spectrum. Such normalization of the data, however, may affect the selection of biomarkers and the biological interpretation of results in unforeseen ways.
Results: First, we study how the outcome of hypothesis tests for differential metabolite concentration is affected by the choice of scale. Furthermore, we observe this interdependence also for different classification approaches. Second, to overcome this problem and establish a scale-invariant biomarker discovery algorithm, we extend linear zero-sum regression to the logistic regression framework and show in two applications to ${}^1$H NMR-based metabolomics data how this approach overcomes the scaling problem.
Availability: Logistic zero-sum regression is available as an R package as well as a high-performance computing implementation that can be downloaded at https://github.com/rehbergT/zeroSum
△ Less
Submitted 22 March, 2017;
originally announced March 2017.
